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Abstract 
Targeted therapies in connective tissue diseases (CTDs) have led to improvements 
of disease-associated outcomes, but life expectancy remains lower compared to general 
population due to emerging co-morbidities, particularly due to excess cardiovascular risk.  
Cardiovascular Magnetic Resonance (CMR) is a noninvasive imaging technique 
which can provide detailed information about multiple cardiovascular pathologies 
without using ionizing radiation. CMR is considered the reference standard for 
quantitative evaluation of left and right ventricular volumes, mass and function, cardiac 
tissue characterization and assessment of thoracic vessels; it may also be used for the 
quantitative assessment of myocardial blood flow with high spatial resolution and for the 
evaluation of the proximal coronary arteries. These applications are of particular interest 
in CTDs, because of the potential of serious and variable involvement of the 
cardiovascular system during their course.  
The International Consensus Group on CMR in Rheumatology was formed in 
January 2012 aiming to achieve consensus among CMR and rheumatology experts in 
developing initial recommendations on the current state-of-the-art use of CMR in CTDs. 
The present report outlines the recommendations of the participating CMR and 
rheumatology experts with regards to: (a) indications for use of CMR in rheumatoid 
arthritis , the spondyloarthropathies , systemic lupus erythematosus,vasculitis of small, 
medium and large vessels, myositis, sarcoidosis (SRC), and scleroderma (SSc);  (b) CMR 
protocols, terminology for reporting CMR and diagnostic CMR criteria for assessment 
and quantification of cardiovascular involvement in CTDs; (c) a research agenda for the 
further development of this evolving field.  
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INTRODUCTION 
The application of new treatment strategies, including targeted therapies in the 
connective tissue diseases (CTDs) has resulted in significant reduction of disease-
associated mortality. However, life expectancy in CTDs remains lower compared to the 
general population (1), predominantly due to excess cardiovascular risk (2-6). Cardiac 
abnormalities in CTDs reflect various pathophysiologic mechanisms, such as systemic 
and vascular inflammation, accelerated atherosclerosis, myocardial ischemia due to 
impaired micro- or macrovascular circulation, abnormal cardiac vessel reactivity, 
myocardial fibrosis, cardiotoxic therapies and cardiac amyloid deposition (7-8). Heart 
involvement in CTDs remains silent and progresses gradually; once it becomes clinically 
overt, patients may present with advanced signs of heart failure and an ominous 
prognosis. (9). This makes the need for tools enabling early diagnosis of cardiovascular 
involvement even more pressing in the CTDs.   
In the clinical arena, echocardiography, nuclear techniques and X-ray coronary 
angiography still remain the cornerstones of cardiac imaging; however, they have serious 
limitations in the early diagnosis of cardiac involvement in CTDs (10-16).  
Cardiovascular Magnetic Resonance (CMR) is a noninvasive, imaging technique 
of great importance for the evaluation of the cardiovascular system. It does not use 
ionizing radiation, and therefore, allows for repeated scans over time. It has been 
successfully used in the diagnostic assessment of diseases of the great vessels, congenital 
heart diseases, iron overload, valvular and pericardial diseases, cardiomyopathies, 
coronary artery disease, heart failure, and myocardial inflammation (17-30).  The 
capability of CMR to perform myocardial tissue characterization (oedema, fat, 
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infiltration, fibrosis) and ischemia detection holds serious promise for the preclinical 
diagnosis of heart involvement in CTDs.  
The limitations of the currently used non-invasive techniques to detect early 
cardiac involvement in CTDs, emphasize the role of CMR as a valuable diagnostic tool in 
the field. The International Consensus Group on CMR in Rheumatology was founded in 
January 2012 to achieve consensus among CMR and rheumatology /cardiologist experts 
and develop recommendations on the current use of CMR in CTDs. Although guidelines 
about the CMR applications in cardiology have been already published by EuroCMR, the 
potential additive value of CMR in CTDs has not been clarified. The present report 
summarises existing evidence and the group’s recommendations, which include: CMR 
protocols, terminology for reporting CMR findings, and diagnostic CMR criteria for 
assessment as well as  quantification of cardiovascular involvement in CTDs and a 
research agenda for the further development of this evolving field.  
METHODS 
 The International Consensus Group on CMR in Rheumatology group was initially 
created by a core group including 3 cardiologists (SM, GP, JL), experienced in cardiac 
disease of CTDs, and well trained in CMR and 3 rheumatologists (GDK, PPS, TD) with a 
special clinical and research interest in cardiac disease of CTDs and good understanding 
of cardiac imaging in order to discuss the early diagnosis of heart involvement in CTDs, 
using currently available non-invasive techniques.  
The core group used a questionnaire to address various clinical queries regarding 
the role of cardiovascular imaging in the early detection of heart involvement in CTDs. 
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Ideas, thoughts and suggestions of the core group were then further discussed with other 
colleagues with a demonstrable interest and expertise in the field, who eventually formed 
the International Consensus Group on CMR in Rheumatology. Group members reviewed 
the existing evidence about pathophysiology of heart disease in CTDs, the advantages 
and disadvantages of currently used non-invasive techniques and the potential utilisation 
of CMR to clarify those aspects of cardiac pathophysiology in CTDs that remain obscure 
using currently available diagnostic techniques. The decision-making process followed to 
formulate the recommendations and any inclusion and/or exclusion criteria was based on 
interaction between the group members via electronic communication and 
teleconferencing. Two members of the core group (SM and TD) collated all the responses 
and drafted various versions of the recommendations.  These were initially reviewed, and 
if necessary amended by the other members of the core group.  The resulting documents 
were circulated to the rest of the group members for detailed comment, further changes, if 
necessary, and final approval. 
 
WHAT IS CMR?  
CMR images are derived from signals produced by protons (hydrogen nuclei) 
present in abundance in the human body. The main sequences used in CMR are shown in 
Table 1 (31).  
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Contraindications and safety considerations 
In CMR, contrast agents are used for the detection of inflammation, fibrosis or 
myocardial ischemia consisting of chelates of gadolinium. Although there is no evidence 
of direct nephrotoxicity, some agents have been linked to systemic fibrosis (known as 
nephrogenic systemic fibrosis), provoking skin fibrosis, tendons contractures, joint 
immobility, internal organ involvement and finally death. Nephrogenic systemic fibrosis 
occurs in patients with glomerular filtration rate of <30 ml/min/1.73 m
2
 or patients on 
hemodialysis.  However no new cases have been reported with some of the newer 
generations of gadolinium and particularly after the implementation of specific 
recommendations (32).  
 Patients with prosthetic heart valves, sternal wires, prosthetic replacements can be 
safely scanned.  Retained epicardial pacing leads, or intracoronary stents can be also 
safely scanned, but at the moment there is no international consensus on the different 
methods to accomplish this. In patients with permanent pacemakers, automated 
implantable cardiac defibrillators or ferro-magnetic cerebrovascular aneurysm clips CMR 
is traditionally contraindicated (34). However, new magnetic resonance -safe or magnetic 
resonance -conditional devices are available and are recommended in cases likely to 
require serial CMR evaluations, such as cardiac sarcoidosis (35). 
Although there is no known risk for use of this imaging technique during pregnancy, 
it is recommended that CMR is avoided during the first trimester. Chelates of gadolinium 
should not be used, as no data are available on possible teratogenic effects. Breastfeeding 
women must discard their milk for 24h after contrast agent injection (31, 34) although, 
there is no evidence to suggest harm to the infant or the mother (36).  
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Indications for CMR 
Current indications of CMR in CTDs are presented in Table 2 
CARDIOVASCULAR INVOLVEMENT IN CTD 
Atherosclerosis and coronary artery disease 
Atherosclerosis-driven pathology is more prevalent in patients with CTDs than in 
the general population and is thought to be the main contributor to the increased 
cardiovascular mortality observed in these diseases (42-44). Ttraditional cardiovascular 
risk factors, such as hypertension, dyslipidemia and insulin resistance are more prevalent 
in many of the CTDs (7), but they are not sufficient to explain the magnitude of the 
increased (cardiovascular disease) CVD risk (45-49). Given that the inflammatory-
immune underpinnings of atherosclerosis and (rheumatoid arthritis) RA share many 
similarities, it has been proposed that a chronic inflammatory state has proatherogenic 
effects on the vascular wall, leading initially to endothelial dysfunction. Indeed, RA, the 
spondyloarthropathies (SpAs), systemic lupus erythematosus (SLE), antiphospholipid 
syndrome and the vasculitides have all been associated with accelerated atherosclerosis 
(50-54). Particularly in RA, in which the risk for coronary artery disease is similar in 
magnitude to the risk conferred by diabetes mellitus (55), atherosclerotic plaques are 
often clinically silent and have an increased propensity to instability and rupture (56), 
leading to higher re-infarction rates with worse outcomes from acute coronary syndromes 
(57). The important role of systemic inflammatory burden in CVD is further supported by 
observations demonstrating improvement in CVD risk with potent anti-inflammatory 
therapeutic strategies in RA (58). While the precise relationship between systemic 
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inflammation and atherosclerosis remains to be determined, immune dysregulation, 
genetic predisposition and immunosuppressive treatment may contribute to increased 
CVD risk in CTDs (59). 
Myocardial dysfunction and heart failure 
Heart failure – whether or not related to ischemic heart disease – also accounts for 
the widening mortality gap between CTDs and the general population (60). In RA the 
prevalence of heart failure is two-fold higher than that in the general population, 
representing a major contributor to mortality (61). Clinical and subclinical impairment of 
myocardial function has been detected in a wide range of CTDs, including RA, SLE, 
systemic sclerosis (SSc), SpA and vasculitis (62-65).  Notably, global indices of cardiac 
function such as left ventricular ejection fraction, lack sensitivity and cannot precisely 
assess the extent of myocardial dysfunction in CTDs, which usually present with diastolic 
dysfunction and a relatively low prevalence of systolic abnormalities (66-70). The risk 
for heart failure remained unchanged after adjusting for classical CVD risk factors and 
ischemic heart disease (71). Therefore, it is thought that these changes may reflect the 
effect of inflammation on myocardial remodeling, suggesting that the mechanisms of 
heart failure in CTDs are strongly linked to immune and adaptive pathways shared by 
CTDs and CVD. In addition, inflammation may affect the autonomic nervous system and 
thus elevate the heart rate, leading to lowering the time for diastolic filling and increasing 
cardiac workload, which in turn contributes to the impaired myocardial perfusion in 
CTDs (72). Furthermore, cardiomyopathy due to fibrosis and/or vascular changes is 
highly prevalent in systemic sclerosis, vasculitis, myositis and sarcoidosis, leading to 
impaired myocardial function and diastolic heart failure (73).  However, similarly to RA, 
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left ventricular systolic function remains normal, and only new imaging modalities can 
identify cardiac abnormalities at a preclinical state (74, 75).  
 
Myocardial and vascular inflammation 
Inflammatory myocardial disease characterised by immune cell infiltration, 
degeneration and necrosis of cardiomyocytes, is a rare but high-risk and probably 
significantly underestimated cardiac complication of CTDs. Autoimmune myocarditis is 
more common in SLE and contributes significantly to CVD morbidity in other conditions 
such as vasculitis, sarcoidosis and inflammatory myopathies (76).  Symptoms are not 
specific and usually the diagnosis is delayed, resulting in irreversible cardiac injury with 
potent life-threatening complications (77).  
Many CTDs are associated with inflammation of large, medium and small blood 
vessels, resulting in intimal hyperplasia and occlusion that may produce ischemic 
manifestations such as stroke, myocardial infarctions, visual abnormalities, limb/jaw 
claudication and digital ulcers (78). Regardless of the vascular territory involved, the 
vasculitic lesions contribute to the increased prevalence of CVD with increased mortality.  
Vasculitis may cause cardiac ischemia, if located in epicardial coronary arteries, in small 
intramural cardiac vessels, or in the aorta (27,79).  
Pulmonary hypertension  
Depending on the exact disease, pulmonary arterial hypertension (PAH) affects 
0.5-15% of patients with CTDs, is associated with worse prognosis and has lower 
therapeutic response than idiopathic PAH. PAH is most commonly seen in systemic 
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sclerosis and is responsible for almost 30% of disease-related deaths (80). Several 
underlying processes such as obstructive proliferative vasculopathy, chronic hypoxemia, 
due to interstitial lung fibrosis and pulmonary veno-occlusive disease have been 
identified as major contributors of increased pressure and vascular resistance in the 
pulmonary circulation (81). Despite advances in diagnostic modalities, almost 50% of 
CTDs with PAH are diagnosed when right heart disease has already progressed to 
advanced stages (82).    
 
APPLICATIONS OF CMR IN CTD 
Coronary artery disease and atherosclerosis 
CMR detection of ischemia 
Myocardial ischemia in CTDs can be due either to coronary artery disease, as in 
SLE and RA, or due to microvascular dysfunction, as in primary or secondary small 
vessel vasculitis (14, 27). CMR detects ischemia by two different ways.  
First, by observation of wall motion abnormalities induced by an inotropic agent 
such as dobutamine (83,84). However, due to the high prevalence of microvascular 
disease in CTDs, which cannot be differentiated from epicardial coronary artery disease 
by wall motion imaging, dobutamine stress CMR is less frequently used in CTD patients; 
it may, however, serve as an alternative to vasodilator perfusion imaging in patients with 
contraindications to contrast agents or vasodilator stress. 
Second, by observation of myocardial perfusion using the first pass of a T1-
shortening contrast agent (first-pass myocardial contrast enhancement) (85,86). Data 
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acquired during intravenous vasodilator-induced hyperemia (adenosine most commonly 
but also dypiridamole) delineate the underperfused regions, due to a lack of vasodilator 
reserve. The spatial resolution of CMR is 2-3 mm x 2-3 mm in-plane, greatly superior to 
nuclear techniques, allowing for a better identification of subendocardial ischemia 
(85,86). The interpretation is most commonly visual, but quantitative approaches are also 
available and have been validated against x-ray angiography, SPECT, and PET (85-90).  
 
CMR in microvascular disease 
Patients, usually women, with signs and symptoms of ischemia and no obstructive 
coronary artery disease often have coronary microvascular dysfunction, which carries an 
adverse prognosis. The gold standard for diagnosis is invasive coronary reactivity testing. 
Traditional noninvasive stress imaging maybe suboptimal  to reveal this entity. CMR can 
be used as an non-invasive alternative to detect coronary microvascular dysfunction in 
this population (91,92). In CTDs, impairment of myocardial microcirculation is one of 
the primary events during the progression of cardiac disease particularly in SSc but also 
in other disease settings such as myositis, SLE and vasculitis.  Diffuse disturbance of the 
myocardial microvasculature due to structural and functional abnormalities of small 
coronary arteries and arterioles results amongst others in repetitive ischaemic episodes 
with intermittent myocardial hypoperfusion contributing to patchy, myocardial fibrosis 
reported in studies employing CMR (93,94).  
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CMR detection of fibrosis  
 CMR is the reference standard for in vivo detection and quantification of 
myocardial scar/fibrosis and can be used to assess the underlying aetiology of heart 
failure. Importantly, not only ischaemic scar, but also scar due to myocarditis and non-
ischaemic cardiomyopathy can be detected and frequently provides a specific diagnosis 
(95).  
Both acute and old scars retain contrast agent and appear bright (96). The 
preferred imaging time for scar detection is 15-20 minutes after gadolinium 
administration, when differences between scar, normal myocardium, and blood pool are 
maximal; therefore, it is referred to as late gadolinium-enhancement (LGE).   
Noninvasive assessment of myocardial viability can be performed by PET, 
SPECT, and Dobutamine echocardiography (97,98). However, different techniques 
assess myocardial viability according to different patterns. Stress echocardiography and 
CMR assess viability as contractile reserve, SPECT as myocardial perfusion defect and 
contrast CMR as myocardial scar. The great advantage of CMR is its ability to assess 
myocardial viability with different parameters within the same examination using only 
one cardiac imaging modality, that is LGE and contractile reserve and in the future with 
metabolic markers also (13C-CMR). Additionally, CMR can detect infarction in as little 
as 1 cm
3
 of tissue, substantially less than in other methods (97,98) and facilitates 
diagnosis of small myocardial scars and diffuse subendocardial fibrosis, missed by other 
imaging techniques (14). Finally, CMR can differentiate between ischemic 
(subendocardial or transmural LGE pattern, following the distribution of coronary 
arteries) (Figure 1) and non-ischemic myocardial fibrosis (patchy, subepicardial or 
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intramyocardial LGE not following the distribution of coronary arteries) (Figure 2). 
Comparison between stress CMR and other stress techniques for detection of myocardial 
ischemia-fibrosis is shown in Table 3. 
Myocardial perfusion defects have been already detected in 40% of women with 
SLE, using nuclear techniques. Early myocardial perfusion defects were also identified 
by CMR in sarcoidosis, RA and SSc and coexisted with normal coronary arteries in the 
majority of cases (99-101).  
LGE, undiagnosed by echocardiographic or nuclear techniques, has been 
described in vasculitis (14, 25-27, 79, 102 – 112), myositis (113-117), SLE (13, 76, 118-
125), RA (13, 27, 125-133), sarcoidosis (125, 134-138) and SSc (125, 139-149). LGE in 
CTDs does not present the typical pattern found in ischemic heart disease 
(subendocardial or transmural lesion in the territory supplied by the occluded vessel). 
However, the possibility of coronary artery disease should always be excluded, when 
evaluating these patients.  
Novel CMR methods such as T1 mapping can add more diagnostic value in 
detecting subtle forms of myocardial fibrosis. The addition of post-contrast T1 mapping 
to pre-contrast T1 mapping acquisitions allows the calculation the gadolinium partition 
coefficient and the extracellular volume fraction of the myocardium provided that there is 
a steady-state equilibrium between the blood pool and the interstitium (150).  
Given that diffuse myocardial fibrosis could be missed by traditional LGE 
imaging where the entire myocardium may be affected more homogeneously, as occurs 
with SSc, T1 mapping and extracellular volume quantification can provide a more 
reliable surrogate estimation of cardiac tissue. This concurs with recent studies 
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demonstrating subclinical heart disease in the form of myocardial fibrosis and 
inflammation in patients with SSc and RA (37-39).  
 
Heart failure (HF) 
Measurement of LV volumes and ejection fraction 
 CMR measures ventricular volumes and ejection fraction (EF) noninvasively and 
without a contrast agent. Echocardiography is still the everyday workhorse for bedside 
evaluation, but CMR has excellent reproducibility and the ability to accurately evaluate 
right ventricular morphology and function, which is of special interest in CTDs (151).  A 
direct comparison of CMR versus echocardiography has shown that for an 80% power 
and a p value of 0.05, the sample size required would be 505 patients for validation of LV 
mass using 2D echo, but only 14 patients for CMR (152). Recently, a great enthousiasme 
developed on applying of 3D Echo for evaluation of volumes and ejection fraction; 
however Crean et al demonstrated statistically significant and clinically meaningful 
differences in right ventricular volumetric measurements between 3D Echo and CMR in 
adults with congenital heart disease, proving the CMR superiority (153). 
 CMR is an important tool in assessing heart failure aetiology (ischemic or 
nonischemic), extent of myocardial ischemia, amount of dysfunctional but viable 
myocardium as well as acute tissue injury (154,155).  Recently, LGE was proven highly 
effective in detecting the mechanism of cardiac dysfunction in patients with newly 
diagnosed heart failure of unclear aetiology, as frequently happens in SLE (156) and RA 
(120-133). It is also clinically effective and economically viable as a gatekeeper to 
coronary angiography. Additional information is provided regarding biventricular 
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assessment and likelihood of benefit from device therapy (157), which has been recently 
applied to CTDs (158).  
 
CMR detection of oedema 
 Myocardial oedema is a feature of acute myocardial injury, associated either with 
inflammation or with myocardial infarction. Oedema alters myocardial T2-relaxation and 
can therefore be detected by T2-weighted CMR imaging (159,160). It is important in 
CTDs, because it allows the detection of cardiac disease acuity (76-79, 102-107), which 
can potentially necessitate additional anti-rheumatic and/or cardiac medication. 
T2-weighted or oedema imaging has been used to assess heart disease acuity in 
CTDs (13, 14, 76-79, 102-107, 119-133). Positive T2-weighted images are indicative of 
myocardial oedema during the acute phase of myocarditis and/or infarction and can be 
identified simultaneously or early before the appearance of LGE (123). Recently, the 
retrospective evaluation of CMR from 246 patients with connective tissue diseases with 
typical or atypical cardiac symptoms revealed abnormal CMR in 32 % (chronic 27%) and 
15 % (chronic 12%) respectively. Lesions due to vasculitis, myocarditis and myocardial 
infarction were evident in 27.4%, 62.6% and 9.6% of CTDs, respectively. Stress studies 
in CTDs with negative CMR revealed coronary artery disease in 20% (125).  
Despite improvement in T2 imaging over the last years detection of myocardial 
oedema remains challenging, due to limitations of the currently used T2-weighted dark-
blood sequences. Recently introduced quantitative T1 and T2 mapping are different 
highly sensitive approaches for detection of myocardial water that allow the 
differentiation of oedematous from non-oedematous myocardium, based on absolute 
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values instead of differences in relative signal intensities (161). In fact T1 mapping may 
have superior performance to T2 mapping for the detection of acute myocardial oedema 
(162). The employment of these techniques provides a discrete quantification of 
myocardial oedema and inflammation which has improved sensitivity to detect 
myocarditis in various conditions including CTD, myocardial infarction and amyloidosis 
(38, 39, 163-168)  
 
Coronary magnetic resonance angiography (MRA) evaluation of coronary arteries 
Coronary MRA can be used to exclude 3-vessel disease and describe the proximal 
course of the coronary arteries (169-172). Although coronary artery computed 
angiography  is considered the best way for fast non-invasive assessment of coronary 
arteries, coronary MRA has the advantage of lack of radiation, which is very important in 
young patients (173-177). However, coronary MRA has limitations in assessing the 
presence and severity of coronary artery disease due to very low diagnostic accuracy of 
this method. 
Indications for coronary MRA include diagnosis of the anomalous origin of 
coronary arteries and evaluation of coronary artery ectasia or aneurysm as in Kawasaki 
disease and other vasculitides (25-27). Coronary MRA allows not only for initial  
diagnosis but also noninvasive, nonradiating follow up of these patients that can be 
achieved neither by coronary artery computed angiography nor by X-Ray coronary 
angiography (178).  
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The combination of coronary MRA with LGE allows simultaneous evaluation of 
coronary arteries and myocardial scar, which is the most important risk factor for major 
cardiac events and mortality (25-27).  
 
MRA evaluation of large and peripheral vessels 
 Recent innovations in CMR offer the possibility of assessing the structure and 
function of the large and peripheral vessels particularly in patients with systemic 
vasculitis  where early recognition and treatment of  inflammatory or stenotic lesions in 
the aorta, pulmonary arteries, subclavian or other peripheral arteries are crucial for the 
reduction of CVD morbidity and mortality (113-119). Peripheral MRA has been 
successfully used in Behcet’s disease (179), Takayasu arteritis, (29, 180-186) and adult-
onset Still’s disease (187).  
 
Myocardial, pericardial, endocardial and vascular inflammation 
Myocardial inflammation 
 Myocarditis (autoimmune or infective) can manifest in different clinical scenario's 
varying from severe hemodynamic collapse to subclinical disease, undetectable by 
standard blood inflammatory markers and can potentially lead to dilated cardiomyopathy 
(188). Additionally, autopsy studies revealed that myocarditis is responsible for 5 to 20 % 
of sudden deaths in young adults and therefore early diagnosis is of great importance 
(189). 
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According to data coming from infective myocarditis, during early stages, it may 
remain undetected by echocardiography because this technique is unable to distinguish 
tissue structural changes (oedema, cell infiltration) that may occur initially without 
associated changes in LVEF. In myocarditis, a decrease in LVEF may not be initially 
evident, while an increase in cardiac troponin was found in only 20% of infective 
myocarditis (190). Additionally, myocardial biopsy, according to ACC/AHA guidelines, 
should be kept only for patients with unexplained new-onset heart failure of < 2 weeks in 
duration associated with a normal-sized or dilated LV with haemodynamic compromise 
and should not be used for screening or as a follow-up tool and is limited by sampling 
error and variation in observer expertise (191). However, similar data about autoimmune 
myocarditis are not currently available, maybe due to silent clinical presentation of 
myocarditis in the majority of these patients  
CMR diagnoses myocarditis using three types of images: T2-weighted (T2W), 
early T1-weighted images (EGE) taken 1 min after injection of the contrast agent, and 
LGE images taken 15 minutes after the injection. T2-W is an indicator of tissue water 
content, which is increased in inflammation or necrosis such as myocarditis and 
myocardial infarction (Figure 2). To enhance the detection of pathologic alterations on 
CMR, images should be obtained early and late after gadolinium injection. Higher levels 
of EGE are due to increased membrane permeability or capillary blood flow. LGE is the 
third parameter, which should be also evaluated (Figure 3). Myocardial necrosis in the 
acute phase plays a major role in LGE formation. A combined CMR approach, using 
T2W in addition to EGE and LGE has a sensitivity of 76%, a specificity of 95.5%, and a 
diagnostic accuracy of 85% for the detection of myocardial inflammation (192). 
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In a study with both CMR and biopsy, histologically active myocarditis was 
found in 19 out of 21 patients with biopsy coincident with the area of LGE, but in only 
one patient in which the biopsy region did not coincide (192). In addition to LGE, other 
CMR sequences, such as EGE and oedema imaging using T2-weighted images can be of 
diagnostic value. In another study, CMR alone diagnosed 80% of patients with chest 
pain, positive necrosis enzymes, and absence of coronary artery disease and the 
diagnostic accuracy was improved when CMR was combined with endomyocardial 
biopsy (95% of patients were diagnosed) (193). In a study comparing CMR accuracy and 
histological findings in an animal model of myocarditis, it was documented that the 
topographic distribution of LGE and histological inflammation seem to 
influence sensitivity, specificity, positive and negative predictive values. Nevertheless, 
positive predictive value for LGE of up to 85% indicates that endomyocardial biopsy 
should be performed "MR-guided". LGE seems to have greater sensitivity than 
endomyocardial biopsy for the diagnosis of myocarditis (194). LGE can also offer 
prognostic information in patients with myocarditis. In a recent work including more than 
200 patients with biopsy-proven myocarditis and CMR, LGE was the best independent 
predictor of both all-cause and cardiac mortality, with a hazard ratio superior to that of 
functional class, EF, or LV volumes (195). 
Increasing amount of evidence demonstrates that T1 mapping may perform as 
well, if not better than the other CMR indices listed above even when it is used as a 
single imaging modality (162-164) (Figure 4).  
CMR has been used for the evaluation of vasculitis (14, 25-27, 79, 102-112), 
myositis (113-119), SLE (13, 76, 120-125), RA (13, 27, 125-133), sarcoidosis (134-139) 
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and SSc (140-150). In many cases, CMR is thought to have identified cardiac disease 
acuity and myocardial inflammation-fibrosis, undetected by routinely used imaging 
techniques, thus facilitating risk stratification of the patients (125). Specifically, in cases 
of cardiac involvement in patients with idiopathic inflammatory myopathies 
(autoimmune myositis) the detection of myocardial involvement is hampered by a lack of 
sensitivity of traditional non-invasive methods, and the finding of elevated 
cardiac troponin T levels that may be due to regenerating skeletal muscle, rather than 
myocardial damage. In these cases, CMR is useful in the evaluation for the presence of 
myocarditis or alternative cardiac pathology (196). 
CMR can also detect primary or secondary diffuse subendocardial vasculitis, 
commonly found in CTDs, which presents with a typical diffuse subendocardial fibrotic 
pattern (14) (Figure 5).  
 
Pericardial inflammation  
Pericarditis is the most common cardiac manifestation in SLE and to a lesser 
extent in RA, spondyloarthropathies, vasculitis, SSc, polymyositis, and sarcoidosis. 
Echocardiography is the ideal technique to diagnose pericarditis and to assess inflow 
patterns into right and left ventricle during inspiration and expiration, together with the 
flows in pulmonary and hepatic veins, thus differentiating constriction from restriction. 
However, CMR is helpful in providing additional information, including tissue 
characterization of the pericardium and myocardium. Using cine sequences, the 
pericardial effusion presents as a bright signal area and in the case of tamponade it is 
accompanied by RV compression. Monitoring of pericardial LGE is useful to assess 
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active pericarditis and treatment response. Constriction causes paradoxical motion of the 
interventricular septum, due to early RV filling, followed by LV filling with 
corresponding displacement of the septum to the RV in late diastole (34). 
Valvular and endocardial inflammation 
 Valvular heart disease is common in CTDs. Antiphospholipid syndrome, either 
primary or secondary can lead to valvular abnormalities and lesions in the form of 
nonbacterial vegetations, conducting mainly to mitral valve and less often to aortic valve 
regurgitation. Antiphospholipid syndrome increases the risk for thromboembolic 
complications. Superimposed bacterial endocarditis can be rarely observed (197). In 
another study of 18-year follow-up of patients with RA, valvular disease was revealed in 
7.9% and occurred more frequently in seropositive RA, with high disease activity despite 
treatment (198). 
While echocardiography is the first-line imaging technique of heart valve disease, 
CMR is a valuable alternative in case of inconclusive results. Particularly, CMR allows 
quantification of aortic and pulmonary regurgitation and precise evaluation of the aorta 
and pulmonary arteries. Indications for CMR in valve diseases include pulmonary valve 
stenosis and regurgitation, aortic valve disease, mitral valve disease and tricuspid valve 
disease.  
Detection of LGE is common in many valvular diseases, particularly in aortic 
stenosis, as part of the hypertrophic response. Several studies suggest that midwall 
fibrosis is an independent predictor of mortality in RA and ankylosing spondylitis (34). 
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Pulmonary hypertension 
 Although CMR is not used to diagnose PAH as right heart catheterization remains 
the gold standard for this procedure, it is an additional tool for the comprehensive 
evaluation of right ventricular function and structure by confirming features, adverse 
remodelling and complications of pulmonary hypertension (e.g. dilated right ventricle, 
right atrium and pulmonary trunk).  
The ASPIRE registry, a study on the accuracy of CMR in PAH, proved that CMR 
is a useful alternative to echocardiography in the evaluation of PAH and supported a role 
for the measurement of left ventricular mass index, LGE and phase contrast imaging in 
addition to the right heart functional indices in CMR evaluation for suspected PAH (199) 
(Figure 6).  
 
WHY USE CMR IN RHEUMATOLOGY? 
 Although recent years have witnessed considerable advances in the management 
of patients with CTDs, premature mortality remains an unresolved and probably a 
neglected issue (200). Recent data suggests that decreased mortality rates between 
individuals with CTDs are more likely to be the reflection of improved survival in the 
general population rather than a result of better treatment (201, 202). Additionally, trends 
in overall and CVD mortality in CTDs have not significantly changed over the last 
decades (202, 203). As CVD disease holds a key role in reduced life expectancy observed 
in these conditions, the emphasis of rheumatology community is shifting from 
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characterization of the increased CVD burden towards the development of effective 
means of assessing, managing and reducing this excess risk.  
For several years the cardiovascular manifestations of CTDs have been 
underdiagnosed and undertreated because of the occult nature and the different 
constellation of clinical signs which make the clinical evaluation more complex, the co-
existence of features of systemic disease but more importantly the diagnostic 
uncertainties due to lack of reliable and validated diagnostic tools. It is worth noting that 
the chronic and relapsing nature of CTDs poses more difficulties in the diagnostic 
assessment of cardiovascular damage, as periods of active disease may result in acute 
inflammatory lesions over pre- existing areas of scar or fibrosis. To make things more 
complicated pre-assessment risk algorithms developed to aid the prediction of risk for 
CVD in general population and various other conditions appear to underestimate future 
CVD events in RA patients suggesting that additional tools should be incorporated in the 
CVD risk stratification and management in this population (204).  
Currently, the most common noninvasive technique used in cardiac imaging is 
echocardiography, due to high availability, portability, low cost, lack of radiation and 
great expertise among cardiologists but cannot distinguish specific etiologies of global or 
regional myocardial dysfunction with accuracy. It is operator dependent, has the 
limitation of the acoustic window, cannot perform detailed tissue characterization and 
cannot define the type of tissue lesions in patients with preserved diastolic or systolic 
function (205). Particularly in CTDs, distinct pathologic processes affecting the 
myocardium may be identified by a more sensitive modality such as CMR allowing a 
better understanding of disease process. For example in SSc, where myocardial 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 27 
involvement constitutes of inflammatory, fibrotic and microvascular components CMR 
has a greater sensitivity (75%) in detecting cardiac abnormalities compared to 
echocardiography (48%) (147). In cases with diastolic dysfunction, although a good 
correlation was observed between CMR and echocardioagraphy, the latter is considered 
practically preferable  to CMR, due to its simplicity and high availability (206).  
Nuclear techniques currently used in cardiology practice for the evaluation of myocardial 
ischemia-fibrosis, have the disadvantages of high cost, radiation, inability to perform 
tissue characterization and low spatial resolution, not allowing the assessment of 
subepicardial, intramyocardial or subendocardial fibrotic lesions, frequently found in 
CTD (10). 
 Finally, X-Ray coronary angiography and endomyocardial biopsy are invasive 
techniques that can be used only in specific clinical indications (10, 11). The limitations 
of the currently available diagnostic techniques mentioned above are more important in 
the management of patients with CTDs because:  
 CTDs usually have silent or oligosymptomatic cardiac presentation (27, 
29) 
 Myocarditis, frequently seen by histopathology in CTDs – with figures 
ranging from 100% in Kawasaki disease and other systemic vasculitides 
during the acute and even the convalescence phase, to 25–30% in 
inflammatory myopathies and SLE (76) - cannot be always detected by 
echocardiography (13) 
 Diffuse, subendocardial vasculitis, either as primary or as secondary heart 
disease in CTDs and small epicardial, intramyocardial and subendocardial 
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fibrosis, due to inflammation or small myocardial infarction might not be 
detected either by echocardiography or by nuclear techniques (13, 14). 
 Acuity of heart involvement cannot be detected by echocardiography or 
by nuclear techniques (13, 14). 
 Large vessel angiography with simultaneous assessment of arterial wall 
inflammation cannot be performed either by echocardiography or nuclear 
techniques (29). 
 Tissue characterization cannot be performed in an accurate and detailed 
way either by echocardiography or by nuclear techniques and cardiac CT 
(13, 14). These techniques may suggest the presence of potential lesions 
but do not provide definitive information. 
 Most CTDs are in female patients who may not be able to perform 
exercise at adequate level, due to arthritis or muscular 
discomfort/weakness; therefore pharmacologic stress CMR, offering a 
noninvasive, non-radiating option, without the limitations of acoustic 
window and/or breast artefacts, may be the best technique for coronary 
artery and cardiac microvascular disease assessment in this population 
(15). 
The rapid technological advances on cardiovascular imaging and the increasing 
number of therapeutic options for treatment of cardiovascular diseases led to an 
impressive development of highly sophisticated imaging techniques, such as CMR that 
has been proposed as an ideal technique for myocardial structure, function, and viability. 
Studies in different disease settings – SSc, RA, SLE - have revealed subtle forms of 
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myocardial inflammation and diffuse myocardial fibrosis as well as interstitial 
myocardial remodeling in asymptomatic patients with apparent normal heart function 
evaluated by echocardiography (37-41, 147). These observations suggest that subclinical 
involvement is associated with preserved global myocardial contractility although mild 
preclinical systolic and diastolic dysfunction was reported in SSc patients. Given the lack 
of sensitivity of conventional imaging modalities to capture early abnormalities in 
inflammatory heart disease during the preclinical phase, CMR can provide useful 
imaging biomarkers for the diagnostic evaluation and identification of high risk patients 
before ventricular dysfunction and irreversible myocardial injury occur. For example the 
detection of asymptomatic myocardial fibrosis in SSc may change the natural history of 
the disease by supporting an early vasodilatory therapeutic intervention – calcium 
channel blockers, angiotensin converting enzyme inhibitors or others-  at the time that it 
is more likely to be effective. Furthermore extensive myocardial oedema and 
inflammation suggesting myocarditis and/or coronary vasculitis in acute, life threatening 
situations resolves diagnostic dilemmas in critically ill patients and provides the 
justification for important clinical decisions regarding the introduction of aggressive, 
immunosuppressive treatment. Although large perspective studies are missing there are a 
few reports highlighting the role of CMR as indicator of treatment efficacy too (108,114). 
Last but not least, CMR can be a valuable tool for addressing unresolved issues and 
questions such as whether systemic inflammatory activity is associated with myocardial 
inflammation and whether anti-rheumatic treatment influences CVD disease positively or 
negatively. In this regard a recently published study assessing cardiac function and 
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morphology by MRI showed improvement of myocardial remodeling and performance in 
RA patients following treatment with tocilizumab (207).  
Guidelines about CMR application have been already recommended by the 
Society for Cardiovascular Magnetic Resonance (208). 
Based on CMR applications proposed by Society for Cardiovascular Magnetic 
Resonance, CMR protocols for evaluation of CTDs were created and presented in Tables 
4, 5.  
RECOMMENDATIONS FOR USE OF CMR IN CTD 
 CMR is a noninvasive, non-radiating imaging technique of special interest for 
assessment of CVD involvement in CTDs. It is the gold standard for the evaluation of: 
LV volumes, mass, ejection fraction of atria and ventricles; LA Structure and function; 
Myocardial inflammation; Myocardial ischemia-necrosis; Inflammation in large, medium 
and small arteries; and ectatic or aneurysmatic coronaries.  
  We suggest that CMR should be considered as a potentially viable diagnostic 
tool for CTDs evaluation in the following cases:  
 To evaluate patients with acute or persistent typical or atypical cardiac 
symptoms and   normal routine noninvasive evaluation. 
 To evaluate the possibility of silent myocardial inflammation in 
inflammatory myopathies with normal routine noninvasive evaluation 
 To clarify the myocardial status in scleroderma with acute symptoms and 
normal routine noninvasive evaluation 
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 To evaluate the possibility of myocardial and/or vascular inflammation in 
primary or secondary vasculitis 
 To evaluate any CTD patient with acute LV dysfunction 
 To evaluate any CTD patient with recent onset of RBBB, LBBB, 
atrioventricular block or evidence of arrhythmia with or without positive 
routine noninvasive evaluation 
 To clarify the myocardial status in technically inconclusive routine 
noninvasive evaluation or in case that the results of this evaluation cannot 
explain the patients’ symptoms and signs.   
 When, although the systemic disease appears under control, the patient 
has typical or atypical cardiac symptoms and noninvasive cardiac 
evaluation is negative 
 If the patients’ symptoms suggest to commence or modify cardiac 
treatment and the routine noninvasive evaluation is normal or doubtful 
 To assess stress myocardial perfusion in CTDs, unable to exercise, with 
poor acoustic window or increased breast size; additionally, in young 
CTDs in whom repeated radiation should be avoided 
 As a gatekeeper for X ray coronary angiography in CTDs with cardiac 
symptoms and mild or abnormal echocardiographic findings 
 
Conclusions 
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In patients with CTDs, the assessment of CVD is now regarded as part of the global 
management along with controlling of disease activity and inflammation. The optimal 
management of CVD risk requires the prompt diagnosis of cardiovascular complications 
however a substantial number of individuals with impairment myocardial function remain 
unrecognized and recent thoughts suggest the need for enhancement of CV risk 
stratification and management with more sensitive approaches. CMR complementing the 
physician’s clinical skills along with echocardiography can also be useful tools to identify 
high-risk patients requiring diligent surveillance and permit earlier intervention, 
potentially reducing the impact of myocardial dysfunction on cardiovascular morbidity 
and mortality in this population.  
Although CMR appears a very exciting diagnostic tool for patients  
with CTDs its use is still in its infancy and for each question answered several more are 
generated.  More importantly data from large prospective studies is lacking. The majority 
of studies to date have been small cross-sectional or even smaller longitudinal 
observation cohorts. Clearly more research focusing on specific cardiac endpoints and 
long term outcomes is warranted to determine whether CMR can improve our diagnostic 
and managing capabilities in CVD risk stratification in CTDs.   
To date, CMR has helped uncover previously undetected (either clinically or 
through other investigations) cardiac disease in patients with CTD: the prognostic value 
of this information remains in most cases elusive; so does any hard evidence that 
intervention based exclusively on such findings is required, what intervention would be 
best for each pathology identified and what might be their risk/benefit ratio.  A non-
exclusive list of potential research directions includes: 
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 Fully characterise the CMR pattern of heart involvement in CTDs 
(acute/chronic phase, rest/pharmacologic stress, oedema, macro-microfibrosis) 
and correlate it with traditional and novel CVD risk factors and clinical 
findings. 
 Assess the role of molecular imaging. Molecular imaging aims at 
characterization and quantification of molecular and cellular processes non-
invasively within intact living organisms. To sense biological processes such 
as cell trafficking in vivo, imaging reporter agents that interact specifically 
with molecular targets and appropriate imaging systems are currently under 
development. In RA, they have been used to facilitate diagnosis and monitor 
therapeutic regimens, and support the development of new therapies (209).  
 Future clinical trials are recommended to evaluate the CMR pattern of heart 
involvement before and after antirheumatic and cardiac treatment, especially 
in patients with CTDs and positive CMR, who have no cardiac symptoms or 
no other evidence of systemically active disease. 
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Table 1. Summary of CMR techniques applied to image different heart conditions.  
CMR techniques 
 
Heart condition imaged 
 
Multislice spin-echo 
 
 
Morphology of the myocardium and fat; blood 
predominantly dark. 
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Multislice SSFP  
 
Morphology of vascular compartments with 
blood predominantly bright.  
 
Cine SSFP 
 
 
 
Functional imaging of wall motion, 
assessment of volumes and ejection fraction, 
wall thickness/thickening 
 
Cine SSFP with tissue tagging Myocardial deformation, strain torsion. 
Pericardial constriction 
 
First-pass contrast-enhancement 
 
 
Myocardial perfusion. 
Myocardial ischemia. 
First-pass contrast-enhancement 
With pharmacological stressor 
Myocardial ischemia 
 
T1-weighted 
 
 
Fat tissue: pericardial, lipomatous metaplasia 
in myocardial scar. 
 
T2-weighted 
 
 
Myocardial edema associated with 
inflammation or acute myocardial infarction. 
 
T2-star (T2*) 
 
 
Myocardial iron deposition 
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Late gadolinium  enhancement 
 
 
Focal replacement fibrosis (scar). 
In acute infarction: area of necrosis. 
Infiltration (e.g. amyloid) 
 
Native T1-mapping 
 
 
Myocardial disease involving myocyte plus 
interstitium 
Myocardial oedema/fibrosis 
 
T2-mapping 
 
 
Oedema quantification 
 
T1-mapping with use of extracellular 
contrast agent 
 
ECV, interstitium, diffuse fibrosis. 
 
ECV= extracellular volume fraction        SSFP= steady-state free precession.  
Table 2. Current indications of CMR in CTDs 
 
CV disease acuity 
Myocarditis 
Myocardial infarction 
Vasculitis 
Myocardial stress-rest perfusion 
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Myocardial fibrosis-infiltration 
Microvascular disease 
Evaluation of coronary arteries, large and 
peripheral arteries 
Assessment of biventricular function  
Constrictive pericarditis 
Evaluation of unexplained heart failure 
Assessment of valvular heart disease (specifically 
quantification of mitral/aortic regurgitation)  
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Table 3.  Comparison of different diagnostic approaches for detection of myocardial 
ischemia-fibrosis 
 Stress ECG Stress Echo Stress 
Nuclear 
 
Stress CMR 
Limitations Inability to 
exercise, poor 
results in 
intermediate risk 
pts and  vasculitis  
Poor acoustic 
window 
Inability to 
detect small 
perfusion 
defects 
CMR 
contraindications 
Scar detection N/A Indirect, 
through wall 
motion 
changes 
Inability to 
detect small or 
subendo-
cardial scars 
High 
Cost Low Low High High 
Availability High High High Low 
Spatial 
resolution 
N/A Low Low High 
Artifacts N/A High High Low 
Operator 
dependency 
Low High Low Low 
Radiation No No Yes No 
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Stress ECG= Stress electrocardiogram 
Stress echo= Stress echocardiography 
Stress Nuclear= Stress radionuclide techniques 
Stress CMR= Stress cardiovascular magnetic resonance 
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Table 4. Proposed rest CMR protocol for CTDs evaluation  
Parameter evaluated CMR methodology for rest study (evaluation of myocarditis, heart 
failure, vasculitis, valvular disease, pericarditis) 
  
Anatomy+Function LVEDV, LVESV, LVEF, RVEDV, RVESV, RVEF, wall motion 
changes using SSFP.   
 
  
Myocardial 
inflammation 
and/or necrosis 
T2 STIR, early (EGE) and late (LGE)  gadolinium (Gd) enhanced 
T1 images (according to JACC White paper) 
T1 and T2 mapping 
  
Coronary arteries Coronary MRA in Kawasaki disease 
  
Large arteries  Aortic and pulmonary artery MRA, either with Gd, or by SSFP, if 
abnormal renal function. Aortic wall assessment using black-blood 
images. 
Peripheral arteries Peripheral arteries MRA using Gd 
 
LVEDV= Left ventricular end-diastolic volume 
LVESV= Left ventricular end-systolic volume 
LVEF= Left ventricular ejection fraction 
RVEDV= Right ventricular end-diastolic volume 
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RVESV= Right ventricular end-systolic volume 
RVEF= Right ventricular ejection fraction 
SSFP= Steady State Free Precession 
T2 STIR= T2-weighted short tau inversion recovery 
MRA=Magnetic resonance angiography 
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Table 5. Proposed stress CMR protocol for CTDs evaluation 
Parameter evaluated CMR methodology for stress study (evaluation of chest pain, 
wall motion or perfusion abnormalities, coronary micro-or 
macro-vascular disease) 
Adenosine stress CMR 
perfusion 
First-pass perfusion sequence: balanced Turbo Field Echo,  
TR 2.8 ms, TE 4 ms, FA 45, 
 slice thickness 8 mm, preparation pulse delay 200 ms 
 
Wall motion 
assessment using 
Dobutamine 
Wall motion changes after Dobutamine, using SSFP sequence, 
if there are contraindications for adenosine (asthma, 
atrioventricular block.  
 
Myocardial fibrosis LGE assessment, using 3D-Turbo field echo sequence, TR 5.1 
ms, TE 2.5 ms, FA 15, slice thickness 8 mm. 
 
 
IR balanced Turbo Field Echo= Inversion recovery Turbo Field Echo 
TR= Repetition time 
TE= Echo time 
FA= Fractional anisotropy 
LGE= Late gadolinium enhancement 
3D-Turbo field echo sequence= three dimensional balanced steady-state free precession 
sequence 
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Figures 
 
Fig 1 
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Fig 2 
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Fig 5 
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Fig 6 
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Legends to figures 
Figure 1. Subendocardial or transmural LGE following the distribution of coronary 
vessels (arrows) can be found, due to coronary artery disease or coronary vessels 
vasculitis. In this case, a transmural LGE in interventricular septum and LV apex, due to 
myocardial infarction after LAD occlusion, was identified in a patient with RA 
Figure 2.  Evidence of local oedema in the anterolateral wall of LV (arrow) can be 
detected by STIR T2 imaging during myocarditis  
Figure 3. Patchy, intramural or subepicardial LGE (arrow), similar to viral myocarditis, 
as in this case, can be found either due to autoimmune myocardial inflammation or focal 
vasculitis, as in this case of a patient with SLE   
Figure 4. Native T1, 25 min T1, T2 and 12 min T1 clockwise from top left, in a patient 
with sinus rhythm and heart failure with LVEF>35%. 
Figure 5.  Diffuse, subendocardial oedema (area indicated by arrow in the left image) 
and diffuse, subendocardial LGE (area indicated by arrow in the right image) not 
following the distribution of coronary arteries can be found either in primary or in 
secondary small vessel vasculitis as in this patient with Churg-Strauss syndrome 
Figure 6. Patchy LGE at the insertion points and concurrent flattering of intraventricular 
septum (arrows), due to pulmonary hypertension in a patient with SSc and PAH 
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Highlights 
. 
 CMR can evaluate symptomatic CTDs with normal routine noninvasive 
findings. 
  CMR can exclude myocarditis and perform stress perfusion in CTDs, 
unable to exercise 
 CMR can evaluate myocardial and/or vascular inflammation in vasculitis 
 CMR can evaluate CTDs with LV dysfunction, block, arrhythmia or 
inconclusive tests 
 CMR can be used in CTDs as a gatekeeper for coronary angiography 
